Long-term Effects of Telmisartan on Blood Pressure, the Renin-angiotensin-aldosterone System, and Lipids in Hypertensive Patients

Overview

Journal Heart Vessels

Specialty Cardiology & Vascular Diseases

Date 2010 Jun 1

PMID 20512446

Citations 6

Authors

Akiko Aoki

Tetsuya Ogawa

Hiroyuki Sumino

Hisao Kumakura

Yoshiaki Takayama

Shuichi Ichikawa

Kosaku Nitta

Affiliations

Soon will be listed here.

Abstract

We prospectively evaluated long-term (12 months) effects of telmisartan on blood pressure (BP), circulating renin-angiotensin-aldosterone levels, and lipids in hypertensive patients. There were 13 men and 11 women, 59 +/- 8.7 years of age (mean +/- SEM), with untreated essential hypertension. The 20-60 mg doses of telmisartan were administered once daily in the morning until BP130/85 was obtained. Blood pressure and plasma renin activity, plasma angiotensin (Ang) I and Ang II, serum angiotensin-converting enzyme (ACE) activity, plasma aldosterone concentration, plasma human atrial natriuretic peptide (hANP) concentration, and serum lipids were obtained 6 and 12 months after starting telmisartan administration. Systolic and diastolic BP were significantly (P < 0.001, P < 0.001) decreased from 162 +/- 3.3 and 97.7 +/- 2.1 mmHg to 128 +/- 3.8 and 79.6 +/- 2.0 mmHg after 12 months of treatment, respectively. Plasma Ang I and Ang II were unchanged at 12 months. Plasma renin activity and serum ACE activity were significantly (P < 0.001, P < 0.05) increased and plasma aldosterone concentration was unchanged during the study period. Total cholesterol levels were unchanged, but serum triglycerides levels were significantly decreased at 12 months (P < 0.01). Plasma hANP showed no significant alteration throughout the 12-month period. In hypertensive patients, telmisartan is a beneficial antihypertensive drug that also lowers serum triglycerides.

Citing Articles

Comparison of Efficacy of Long-term Oral Treatment with Telmisartan and Benazepril in Cats with Chronic Kidney Disease.

Sent U, Gossl R, Elliott J, Syme H, Zimmering T J Vet Intern Med. 2015; 29(6):1479-87.

PMID: 26474314 PMC: 4895689. DOI: 10.1111/jvim.13639.

Long-term effect of telmisartan on Alzheimer's amyloid genesis in SHR-SR after tMCAO.

Kurata T, Lukic V, Kozuki M, Wada D, Miyazaki K, Morimoto N Transl Stroke Res. 2014; 6(2):107-15.

PMID: 24435631 DOI: 10.1007/s12975-013-0321-y.

Relationship between status of plasma atrial natriuretic peptide and heart rate variability in human subjects.

Kasamaki Y, Izumi Y, Ozawa Y, Ohta M, Tano A, Watanabe I Heart Vessels. 2012; 28(2):208-14.

PMID: 22370591 DOI: 10.1007/s00380-012-0237-6.

Telmisartan: a review of its use in cardiovascular disease prevention.

Frampton J Drugs. 2011; 71(6):651-77.

PMID: 21504246 DOI: 10.2165/11206710-000000000-00000.

Relationship between cardio-ankle vascular index (CAVI) and coronary artery calcification (CAC) in patients with type 2 diabetes mellitus.

Mineoka Y, Fukui M, Tanaka M, Tomiyasu K, Akabame S, Nakano K Heart Vessels. 2011; 27(2):160-5.

PMID: 21476051 DOI: 10.1007/s00380-011-0138-0.

References

Yamamoto T, Shirayama T, Takahashi T, Matsubara H . Altered expression of Na+ transporters at the mRNA level in rat normal and hypertrophic myocardium. Heart Vessels. 2009; 24(1):54-62. DOI: 10.1007/s00380-008-1071-8. View

Timmermans P, Wong P, Chiu A, Herblin W, Benfield P, Carini D . Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993; 45(2):205-51. View

Galzerano D, Tammaro P, Del Viscovo L, Lama D, Galzerano A, Breglio R . Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. Am J Hypertens. 2005; 18(12 Pt 1):1563-9. DOI: 10.1016/j.amjhyper.2005.06.011. View

Kang P, Landau A, Eberhardt R, Frishman W . Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system. Am Heart J. 1994; 127(5):1388-401. DOI: 10.1016/0002-8703(94)90061-2. View

Campbell D, Kladis A, Valentijn A . Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol. 1995; 26(2):233-40. DOI: 10.1097/00005344-199508000-00009. View

Agata J, Ura N, Yoshida H, Shinshi Y, Sasaki H, Hyakkoku M . Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res. 2007; 29(11):865-74. DOI: 10.1291/hypres.29.865. View

Carey R, Wang Z, Siragy H . Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension. 2000; 35(1 Pt 2):155-63. DOI: 10.1161/01.hyp.35.1.155. View

Matsubara H . Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res. 1998; 83(12):1182-91. DOI: 10.1161/01.res.83.12.1182. View

Yusuf S, Teo K, Pogue J, Dyal L, Copland I, Schumacher H . Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358(15):1547-59. DOI: 10.1056/NEJMoa0801317. View

10.

Shibasaki Y, Mori Y, Tsutumi Y, Masaki H, Sakamoto K, Murasawa S . Differential kinetics of circulating angiotensin IV and II after treatment with angiotensin II type 1 receptor antagonist and their plasma levels in patients with chronic renal failure. Clin Nephrol. 1999; 51(2):83-91. View

11.

Cohn J, Anand I, Latini R, Masson S, Chiang Y, Glazer R . Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation. 2003; 108(11):1306-9. DOI: 10.1161/01.CIR.0000091234.45664.62. View

12.

Kojima S, Inoue I, Hirata Y, Saito F, Yoshida K, Abe H . Effects of changes in dietary sodium intake and saline infusion on plasma atrial natriuretic peptide in hypertensive patients. Clin Exp Hypertens A. 1987; 9(7):1243-58. DOI: 10.3109/10641968709160047. View

13.

Wagner J, Drab M, Bohlender J, Amann K, Wienen W, Ganten D . Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain. Clin Exp Hypertens. 1998; 20(2):205-21. DOI: 10.3109/10641969809053215. View

14.

Ogihara T, Shima J, Hara H, Tabuchi Y, Hashizume K, KUMAHARA Y . Changes in plasma atrial natriuretic polypeptide concentration during head-out water immersion and saline infusion in normal men. Jpn Heart J. 1987; 28(1):41-51. DOI: 10.1536/ihj.28.41. View

15.

Parker A, Azevedo E, Baird M, Smith S, Arnold J, Humen D . ARCTIC: assessment of haemodynamic response in patients with congestive heart failure to telmisartan: a multicentre dose-ranging study in Canada. Am Heart J. 1999; 138(5 Pt 1):843-8. DOI: 10.1016/s0002-8703(99)70008-6. View

16.

Gavras I, Gavras H . Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin. 1999; 15(1):15-24. DOI: 10.1185/03007999909115169. View

17.

Yamamoto T, Hiromoto J, Kikuchi Y, Oka M, Takatori O . Correlations among blood levels of renin-angiotensin-aldosterone, bradykinin, and catecholamines in healthy subjects. Clin Chim Acta. 1989; 181(2):197-200. DOI: 10.1016/0009-8981(89)90188-5. View

18.

Fernandes-Santos C, de Souza Mendonca L, Mandarim-de-Lacerda C . Favorable cardiac and aortic remodeling in olmesartan-treated spontaneously hypertensive rats. Heart Vessels. 2009; 24(3):219-27. DOI: 10.1007/s00380-008-1104-3. View

19.

Sharpe M, Jarvis B, Goa K . Telmisartan: a review of its use in hypertension. Drugs. 2001; 61(10):1501-29. DOI: 10.2165/00003495-200161100-00009. View

20.

Bauer I, Reams G, Wu Z . Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension. J Hum Hypertens. 1995; 9(4):237-43. View